Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $58.36 million versus the consensus estimate of $56.96 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.